melanoma
RICHMOND, Va. (August 3, 2009) -- An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma -- a cancer that is highly resistant to current treatment strategies.
Washington, DC -- Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies.
Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.
A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma.
"Single-Shot" Vaccines May Protect Against H5N1 Influenza Virus
Nobody likes Mondays. Here is some cancer news to lift your mood.
Scientists from the Queensland Institute of Medical Research (QIMR) have found two new genes that together double a person's risk of developing melanoma.
BOSTON--Dana-Farber Cancer Institute scientists' discovery of a cancer-causing gene -- the first in its family to be linked to cancer -- demonstrates how the panoramic view of genomics and the close-up perspective of molecular biology are needed to determine which genes are involved in cancer and which are mere bystanders.
The vast majority of cancer deaths are due to metastasis, the spread of cancer cells from its primary site to other parts of the body. These metastatic cells tend to move more than their non-metastatic variants but this movement is poorly understood. Scientists are studying cancer cells intently with the hope they can learn to control the movements of the dangerous cells.
June 9, 2009 -- Many cancerous tumors possess a genetic mutation that disables a tumor suppressor called PTEN. Now researchers at Washington University School of Medicine in St. Louis have shown why inactivation of PTEN allows tumors to resist radiation therapy.
If you had cancer and a genetic test could predict the risk of the tumor spreading aggressively, would you want to know -- even if no treatments existed to help you?
An overwhelming majority of eye cancer patients would answer yes, according to a new UCLA study published in the June edition of the Journal of Genetic Counseling.
ORLANDO - A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.
PITTSBURGH, May 30 ? Researchers from the University of Pittsburgh Cancer Institute (UPCI) have identified eight genes that help predict a melanoma patient's response to treatment. The new findings are being presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), May 29 to June 2, in Orlando, Fla.
In a new study published in Disease Models & Mechanisms, scientists use the zebrafish to gain insight into the influence of known cancer genes on the development and progression of melanoma, an aggressive form of human skin cancer with limited treatment options.
The following news tips are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2, 2008.
Abstract # 9075, 8 a.m. to noon on Monday, June 1, 2009
Antiparasitic drug is promising in animal studies of metastatic melanoma
